Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of rheumatoid arthritis (RA) for \>= 3 months who also fulfill the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for RA.~* Subjects have been receiving conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) therapy \>= 3 months and on a stable dose for \>= 4 weeks prior to the first dose of study drug.~* Subject has \>= 6 swollen joints (based on 66 joint counts) and \>= 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.~* Subjects with prior exposure to at most one biological disease-modifying anti-rheumatic drug (bDMARD) may be enrolled (up to 20% of total number of subjects) after the required washout period. Specifically, prior to enrollment:~  1. Subjects with limited exposure to bDMARD (\< 3 months) OR~ 2. Subjects who are responding to bDMARD therapy but had to discontinue due to intolerability (regardless of treatment duration).~Exclusion Criteria:~* Prior exposure to any Janus kinase (JAK) inhibitor~* Subjects who are considered inadequate responders (lack of efficacy) to bDMARD therapy, after minimum 3 months treatment, as determined by the Investigator.~* History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA (including but not limited to gout, systemic lupus erythematosus, psoriatic arthritis, axial spondyloarthritis \[SpA\] including ankylosing spondylitis and non-radiographic axial SpA, reactive arthritis, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia \[currently with active symptoms\]). Current diagnosis of secondary Sjogren's Syndrome is permitted.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo / Upadacitinib 7.5 mg (Type: EXPERIMENTAL): Period 1: Participants will receive placebo once daily for 12 weeks.~Period 2: Participants will receive Upadacitinib 7.5 mg once daily for 248 weeks.
- Placebo / Upadacitinib 15 mg (Type: EXPERIMENTAL): Period 1: Participants will receive placebo once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks.
- Placebo / Upadacitinib 30 mg (Type: EXPERIMENTAL): Period 1: Participants will receive placebo once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks.
- Upadacitinib 7.5 mg / Upadacitinib 7.5 mg (Type: EXPERIMENTAL): Period 1: Participants will receive upadacitinib 7.5 mg once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 7.5 mg once daily for 248 weeks.
- Upadacitinib 15 mg / Upadacitinib 15 mg (Type: EXPERIMENTAL): Period 1: Participants will receive upadacitinib 15 mg once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks.
- Upadacitinib 30 mg / Upadacitinib 30 mg (Type: EXPERIMENTAL): Period 1: Participants will receive upadacitinib 30 mg once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).